血管生成是形成新血管的生理过程，在癌症、糖尿病和各种炎症性疾病等看似无关的疾病中具有病理重要性。针对血管生成的治疗已显示出治疗这些类型疾病的希望，但目前的抗血管生成药物在递送和副作用方面存在严重局限性。这就需要探索替代方法，例如基于生物分子的药物。蛋白质、脂质和寡核苷酸最近在生物医学中变得流行，特别是作为治疗药物的生物相容性成分。它们优异的生物利用度以及潜在的生物活性和免疫原性特性使它们成为药物发现或药物输送系统的主要候选者。基于脂质的脂质体已成为靶向纳米颗粒 (NP) 递送的标准载体，而蛋白质和核苷酸 NP 则显示出作为智能 NP 进行环境敏感递送的前景。它们的治疗应用最初因循环时间短和制造困难而受到阻碍，但纳米制造和纳米粒子工程的最新发展已经找到了克服这些缺点的方法，极大地提高了生物分子纳米粒子的实用性。在这篇综述中，我们将简要讨论基于生物分子的纳米颗粒如何改善基于抗血管生成的治疗。© 2024 Canlas 和 Park。

Angiogenesis is a physiological process of forming new blood vessels that has pathological importance in seemingly unrelated illnesses like cancer, diabetes, and various inflammatory diseases. Treatment targeting angiogenesis has shown promise for these types of diseases, but current anti-angiogenic agents have critical limitations in delivery and side-effects. This necessitates exploration of alternative approaches like biomolecule-based drugs. Proteins, lipids, and oligonucleotides have recently become popular in biomedicine, specifically as biocompatible components of therapeutic drugs. Their excellent bioavailability and potential bioactive and immunogenic properties make them prime candidates for drug discovery or drug delivery systems. Lipid-based liposomes have become standard vehicles for targeted nanoparticle (NP) delivery, while protein and nucleotide NPs show promise for environment-sensitive delivery as smart NPs. Their therapeutic applications have initially been hampered by short circulation times and difficulty of fabrication but recent developments in nanofabrication and NP engineering have found ways to circumvent these disadvantages, vastly improving the practicality of biomolecular NPs. In this review, we are going to briefly discuss how biomolecule-based NPs have improved anti-angiogenesis-based therapy.© 2024 Canlas and Park.